Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.oooo.2016.04.020 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diclofenac Enhances the Response of BRAF Inhibitor to Melanoma Through ROS/p38/p53 Signaling.
Clin Exp Pharmacol Physiol
March 2025
Department of Dermatology, Fudan University Huashan Hospital, Shanghai, China.
BRAF inhibitors (BRAFi) represent a cornerstone in melanoma therapy due to their high efficacy. However, the emergence of resistance causes a significant challenge to their clinical utility. This study aims to investigate the potential of diclofenac as a sensitizer for BRAFi therapy in melanoma and to elucidate its underlying mechanism.
View Article and Find Full Text PDFCutaneous adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis.
Front Pharmacol
December 2024
Department of Pharmacy, Shaoxing People's Hospital, Shaoxing, China.
Aim: Cutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared with BRAF inhibitor alone.
Method: PubMed, Cochrane, Embase and Web of Science were systematically searched for BRAF and MEK inhibitors from database inception through 10 May 2024.
Synergistic ROS Reduction Through the Co-Inhibition of BRAF and p38 MAPK Ameliorates Senescence.
Antioxidants (Basel)
November 2024
Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon 22012, Republic of Korea.
Reactive oxygen species (ROS)-mediated damage to macromolecules and cellular organelles is one of the major causes of senescence. Therapeutic strategies that lower ROS levels have been proposed as important treatments for senescence, but effective mechanisms for reducing ROS levels have not been discovered. Here, we aimed to find a combination that has a synergistic effect on ROS reduction using senomorphics known to reduce ROS.
View Article and Find Full Text PDFNeutrophilic Panniculitis Secondary to BRAF and MEK Inhibitor Therapy to Treat Stage IIIa Cutaneous Melanoma.
J Cutan Pathol
January 2025
Department of Dermatology, San Antonio Uniformed Services Health Consortium (SAUSHEC), San Antonio, Texas, USA.
Panniculitides are a group of inflammatory disorders of the subcutaneous fat that have been reported as a rare complication of both a serine threonine kinase BRAF inhibitor monotherapy and BRAF inhibition in combination with a mitogen activated protein kinase (MEK) inhibitor combination therapy used to treat metastatic melanoma. The cutaneous manifestations of BRAF and BRAF/MEK therapies have been well documented, but neutrophilic panniculitis remains a less common complication with fewer case reports. Physician awareness of this complication when following patients on similar targeted therapies can decrease delays in appropriate management.
View Article and Find Full Text PDFEfficacy of Combined Encorafenib and Binimetinib Treatment for Erdheim-Chester Disease Harboring Concurrent BRAF and KRAS Mutations: A Case Report.
Cancer Rep (Hoboken)
December 2024
Department of Hematology and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Article Synopsis
- Erdheim-Chester disease (ECD) is a rare histiocytic condition often linked to mutations in the MAPK/ERK signaling pathway, with this case revealing concurrent BRAF and KRAS mutations.
- A 70-year-old male presented with symptoms indicative of ECD, and upon genetic testing, both BRAF and KRAS mutations were identified, allowing for targeted treatment with BRAF and MEK inhibitors.
- The combination therapy using encorafenib and binimetinib led to significant symptom relief and imaging improvements, marking the first reported use of this treatment in ECD patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!